Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.
For the 10,000+ people
who have been treated with
SPINRAZA worldwide,*
victories are personal.
*Based on commercial patients, early access patients, and clinical trial participants through December 2019.
Discover SPINRAZA: the first FDA-
approved treatment for SMA
6+ years
Safety and efficacy
evaluated
in the longest
clinical trial in
SMA to date
3x/year
SPINRAZA is delivered directly to
the central nervous system (CNS)
where
motor neuron loss begins.
After
initial loading doses,
SPINRAZA is
given 3 times a year.
From 3 days† to 80 years old‡§
There’s someone from almost every age group who has been treated with SPINRAZA.
†Includes clinical trial patients.
‡Clinical studies of SPINRAZA did not include sufficient numbers of subjects aged 65 and older to determine
whether they respond differently from younger patients.
§Based on commercial patients in the US (including Puerto
Rico) through December 2019.
Safety & side effects
The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. These are not all of the possible side effects of SPINRAZA.
